SCHEMBL752160

SCHEMBL752160

COc1ccc(C=O)cc1OCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
PDCD1 Q15116 1/20 0.65
CD274 Q9NZQ7 1/20 0.65
TSHR P16473 1/20 0.62
AMY1A P0DUB6 1/20 0.60
MAPT P10636 3/20 0.59
NPC1 O15118 1/20 0.59
HTT P42858 1/20 0.59
RAB9A P51151 1/20 0.59
FDPS P14324 1/20 0.58
TTR P02766 1/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
TACR2 P21452 1/20 0.57
APP P05067 2/20 0.56
LMNA P02545 1/20 0.56
SMPD1 P17405 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC8 Q9BY41 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377794 1.00 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2PDCD1CD274TSHR
SCHEMBL161066 0.94 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2PDCD1CD274TSHR
SCHEMBL7784719 0.92 PDCD1 (0.74) ALDH1A1SMN1; SMN2PDCD1CD274TSHR
SCHEMBL584489 0.91 TACR2 (0.62) ALDH1A1SMN1; SMN2PDCD1CD274MAPT
SCHEMBL29446267 0.91 TACR2 (0.62) ALDH1A1SMN1; SMN2PDCD1CD274MAPT
SCHEMBL19658009 0.89 FDPS (0.65) ALDH1A1SMN1; SMN2PDCD1CD274MAPT
SCHEMBL2463491 0.89 NPC1 (0.63) ALDH1A1SMN1; SMN2PDCD1CD274MAPT
SCHEMBL9587052 0.88 CYP1A1 (0.65) ALDH1A1PDCD1CD274AMY1AHTT
SCHEMBL9587050 0.88 CYP1A1 (0.65) ALDH1A1PDCD1CD274AMY1AHTT
SCHEMBL8698472 0.88 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2PDCD1CD274TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10751330-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-25 US claimed
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-05-14 US claimed
US-10092550-B2 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof IONS PHARMACEUTICAL S.À R.L. (LU) 2018-10-09 US claimed
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-04-20 US claimed
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2017-02-16 US claimed
US-9512063-B2 Process for the preparation of advantame DIVI'S LABORATORIES LIMITED (IN) 2016-12-06 US claimed
WO-2016181220-A2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF IONS PHARMACEUTICAL S.À R.L. (LU) 2016-11-17 WO claimed
US-20160304439-A1 PROCESS FOR THE PREPARATION OF ADVANTAME DIVI'S LABORATORIES LIMITED (IN) 2016-10-20 US claimed
CN-103980152-B Benzamide compounds with anti-tumor activity and its preparation method and application XI'AN JIAOTONG UNIVERSITY (CN) 2016-04-27 CN claimed
CN-103980153-B Dibenzoyl amine compound with anti-tumor activity and its preparation method and application XI'AN JIAOTONG UNIVERSITY (CN) 2016-01-20 CN claimed
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions CONSTAR INTERNATIONAL, INC (US) 2009-11-12 US claimed
CN-101193976-A Oxygen scavenging compositions and packages comprising the same CONSTAR INT INC (US) 2008-06-04 CN claimed
EP-1848659-A2 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS Constar International Inc. (US) 2007-10-31 EP claimed
WO-2006088889-A2 OXYGEN SCAVENGING COMPOSITIONS AND PACKAGING COMPRISING SAID COMPOSITIONS CONSTAR INTERNATIONAL, INC. (US) 2006-08-24 WO claimed
US-20060180790-A1 polyesters; melt polymerization; packaging CONSTAR INTERNATIONAL INC. (US) 2006-08-17 US claimed
US-20060084176-A1 Detection of uronium salts YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-04-20 US claimed
EP-0674232-B1 Recording sheets XEROX CORP (US) 2000-05-31 EP claimed
US-5931995-A Ink compositions XEROX CORPORATION (US) 1999-08-03 US claimed
US-5663022-A Recording sheets XEROX CORPORATION (US) 1997-09-02 US claimed
EP-0674232-A2 Recording sheets XEROX CORPORATION (US) 1995-09-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10751330-B2 Human therapeutic agents INMT, HNMT, HASPIN ALDH1A1 371/4885SMN1; SMN2 2552/4885PDCD1 1538/4885
US-20170042865-A1 THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, CPT1A ALDH1A1 460/4885SMN1; SMN2 3486/4885PDCD1 2048/4885
US-10092550-B2 Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof INMT, HNMT, CPT1A ALDH1A1 460/4885SMN1; SMN2 3486/4885PDCD1 2048/4885
US-20160304439-A1 PROCESS FOR THE PREPARATION OF ADVANTAME TASP1, ASPH, COMT ALDH1A1 312/4885SMN1; SMN2 1642/4885PDCD1 3151/4885
US-20090278087-A1 Oxygen Scavenging Compositions and Packaging Comprising Said Compositions LPO, GPX4, PRDX3 ALDH1A1 548/4885SMN1; SMN2 651/4885PDCD1 2777/4885
US-20170105975-A1 THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF INMT, HNMT, COMT ALDH1A1 320/4885SMN1; SMN2 3053/4885PDCD1 2177/4885
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN ALDH1A1 371/4885SMN1; SMN2 2552/4885PDCD1 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.